Alife Health raises 22 million in a Series A

Alife Health, the fertility technology company building artificial intelligence tools to advance in-vitro fertilization (IVF), announced today it has raised $22 million in Series A financing co-led by existing Seed lead Deena Shakir at Lux Capital, and new investors Rebecca Kaden at Union Square Ventures and Anarghya Vardhana at Maveron, both of whom will also be joining Alife's Board of Directors. Alife's mission is to enhance IVF clinical decision-making with personalized, data-driven patient insights, ultimately helping clinicians maximize each patient's chances of success while lowering costs and barriers to access. Today, the 180 million people around the world who struggle with infertility face treatment options that are both expensive and inaccessible. The average IVF cycle can cost up to $25,000 in the U.S., and patients typically go through 3 to 5 cycles to have a baby. Successful pregnancies from IVF rely on a complex set of clinical decisions to deliver the optimal care for each patient.